anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
LYRICA treatment may cause weight gain. In LYRICA controlled clinical trials in adult patients of up to 14 weeks, a gain of 7% or more over baseline weight was observed in 9% of LYRICA-treated patients and 2% of placebo-treated patients. Few patients treated with LYRICA (0.3%) withdrew from controlled trials due to weight gain. LYRICA associated weight gain was related to dose and duration of exposure, but did not appear to be associated with baseline BMI, gender, or age. Weight gain was not limited to patients with edema [see Warnings and Precautions (5.7)].

Although weight gain was not associated with clinically important changes in blood pressure in short-term controlled studies, the long-term cardiovascular effects of LYRICA-associated weight gain are unknown.

Among diabetic patients, LYRICA-treated patients gained an average of 1.6 kg (range: -16 to 16 kg), compared to an average 0.3 kg (range: -10 to 9 kg) weight gain in placebo patients. In a cohort of 333 diabetic patients who received LYRICA for at least 2 years, the average weight gain was 5.2 kg.

While the effects of LYRICA-associated weight gain on glycemic control have not been systematically assessed, in controlled and longer-term open label clinical trials with diabetic patients, LYRICA treatment did not appear to be associated with loss of glycemic control (as measured by HbA1C).
An activity tracker includes a device that includes a sensor component, a radio, a housing, and a removable portion. The sensor component is configured to obtain bicycle route information based on one or more sensors. The radio is configured to wirelessly communicate the bicycle route information to a remote computing device. The housing includes at least a portion of the sensor component and the radio. The removable portion includes a battery. The removable portion and the housing, when coupled, create a watertight seal to protect electronic components of the device.
Kidney toxicity was observed in studies in male mice and rats; findings in urinary bladder were observed in male mice. 

In male mice, golodirsen was administered weekly for 12 weeks by intravenous injection (0, 12, 120, or 960 mg/kg) or for 26 weeks by subcutaneous injection (0, 120, 300, or 600 mg/kg). In the 12-week study, microscopic findings in kidney (tubular dilatation, basophilic or eosinophilic casts, vacuolation), correlated with increases in serum markers of renal function (e.g., urea nitrogen, creatinine), were observed primarily at the highest dose tested; hypertrophy of the transitional epithelium of the ureter or urinary bladder was observed at all doses. In the 26-week study, renal tubular degeneration and degeneration of the transitional epithelium of the urinary bladder were observed at all doses. 

In male rats, intravenous administration of golodirsen (0, 60, 100, 300, or 600 mg/kg) weekly for 13 weeks resulted in tubular degeneration at all but the lowest dose tested; at the high dose, the microscopic changes were accompanied by increases in serum urea nitrogen. 

In male monkeys, intravenous administration of golodirsen (0, 80, 200, or 400 mg/kg) weekly for 39 weeks resulted in microscopic changes in kidney (basophilia, dilatation, or mononuclear cell infiltration) at all doses, which correlated with increases in serum markers of renal function (urea nitrogen, creatinine) at the highest dose tested.
Over the 8-week project, families were asked to try eight different vegetable recipes from a choice of 12. All family members could participate in the home activities as the families wished. Families were also asked to complete a weekly recipe cooking tracking sheet.
Introduction and Aims All athletes are vulnerable to acute traumas or cumulative injuries throughout their sports life. Thus, screening the health levels of athletes and investigating whether they have overuse injuries is essential both to prevent acute traumas and improve health and performance. There is no valid and reliable subjective measurement tool to perform this screening in athletes in Turkish currently. However, the valid and reliable "Oslo Sports Trauma Research Centre Overuse Injury Questionnaire - (OSTRC)" questionnaires are available in English. So the investigators aimed to adapt the OSTRC- Overuse (OSTRC-O) and the OSTRC-Health Questionnaire (OSTRC-H) into Turkish.

Methods Permission was obtained from the developer authors. Then, ethical approval was acquired from the clinical researches ethics committee. Questionnaires were adapted into Turkish systematically. A pilot study was conducted to ensure the accuracy of meaning and comprehensibility of translated questionnaires. Next, the validity and reliability of the new tools were estimated. 72 athletes aged between 18 and 35, who can understand and speak Turkish fluently from various sports branches, were included. Informed consent was obtained from all athletes. The demographics of the participants were recorded. All participants were administered the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ), Nottingham Health Profile (NHP), OSTRC-O, and OSTRC-H questionnaires. The OSTRC-O OSTRC-H and CMDQ questionnaires were repeated weekly for six weeks on 33 athletes.

Reliability was analyzed by internal consistency and test-retest methods. The validity of the scale was evaluated in terms of content validity and concurrent validity. Content validity was verified with reports of participants at the end of the sixth week. To evaluate the concurrent validity, total OSTRC scores were compared with the total scores of CMDQ and NHP. Correlations of the OSTRC-O and OSTRC-H change scores with CMDQ change scores separately were assessed throughout the six weeks in point of the Effect Size (ES) for responsiveness. Receiver Operating Characteristic (ROC) Curve test based on the area under the curve (AUC) depicted to define the performance of these assessment tools. Statistical analyses were performed with the Statistical Package for Social Sciences Program.
Use of betanidine and derivatives thereof for preparing a drug for treating atherosclerosis. The effect of the drug consists in inducing the regression of lesions caused by atherosclerosis after being administered. Said drug may contain betanidine, isobetanidine or a derivative thereof in an individual manner or in multiple combinations. Likewise, said drug may contain other pharmaceutical products. Any administration form may be used for being applied. Any drug containing betanidine or a derivative thereof, which is intended for treating atherosclerosis may be administered to any eukaryotic organism, including human beings.
This invention relates to the AIB1 protein as a coactivator that potentiates the transcriptional activity of nuclear hormone receptors. The gene is amplified in a subset of human breast cancers. One splice variant of AIB1 transcribes a mRNA that lacks the exon 3 sequence. Δ3-AIB1 mRNA encodes a 130 kDa protein that lacks the N-terminal basic helix-loop-helix and a portion of the PAS dimerization domain. This 130 kDa protein was detected in MCF-7 breast cancer cells at levels 5-10% of the full length protein, whereas in non transformed mammary epithelium lines the Δ3-AIB1 protein is present at significantly lower levels compared to the full length AIB1. The abundance of Δ3-AIB1 mRNA is increased in human breast cancer specimens relative to that in normal breast tissue. Functional reporter gene assays revealed that the ability of Δ3-AIB1 to promote transcription mediated by the estrogen or progesterone receptors was significantly greater than that of the full-length protein. The Δ3-AIB1 isoform was also more effective than AIB1 in promoting transcription induced by epidermal growth factor. Thus, over expression of Δ3-AIB1 plays an important role in sensitizing breast tumor cells to hormone or growth factor stimulation.
PURPOSE: Modular cementless knee arthroplasty systems are capable of precise reconstruction of the mechanical axis. However, they are considered more susceptible to complications. In contrast, non-modular cemented systems are said to be more forgiving and show good long-term results. The aim of this study was to investigate the resulting leg axis after implantation of a non-modular cemented rotating hinged knee prosthesis. Furthermore, potential risk factors for the occurrence of malalignment and complications should be identified.
METHODS: Between 2005 and 2015, 115 patients could be included in this monocentric retrospective cohort study. All patients underwent primary hinged non-modular cemented total knee arthroplasty. Preoperative and postoperative standardized long radiographs were analysed to determine resulting leg axis. Furthermore, epidemiological and intraoperative data as well as perioperative complications were surveyed.
RESULTS: Average leg axis was 5.8° varus preoperatively and 0.6° valgus postoperatively. Considering an axis deviation of 3° as the target corridor, 27% of all cases examined were outside the desired range. 21% cases showed a femoral deviation from the target corridor and 15% showed a tibial deviation. There was a significant relationship between the preoperative mLDFA and the mechanical alignment of the femoral component (R = 0.396, p < 0.001) as well as between the preoperative mMPTA and the mechanical alignment of the tibial component (R = 0.187, p = 0.045). The mean operative duration was 96 min. No periprosthetic fractures were observed within the study cohort.
CONCLUSION: The main result of the present work is that a non-modular cemented rotating hinged knee arthroplasty system can reconstruct the mechanical leg axis precisely and comparable to modular cementless and unconstrained total knee prostheses. Component malalignment is primarily dependent upon extraarticular deformity preoperatively. Periprosthetic fracture rates and duration of surgery were lower compared with current literature.
LEVEL OF EVIDENCE: Level III: Retrospective cohort study.
The invention discloses a PEGylated asparaginase and an application thereof. PEG is coupled to amino on N-terminal of one or two subunits of L-asparaginase, and the molecular weight of PEG is 30-40KDa. PEG is preferentially selected from branching type PEG whose activating groups are aldehyde groups. Compared with commercially available PEGylated asparaginase products, the PEGylated asparaginase has the advantages of longer half life, lower immunogenicity, homogeneous components, and higher specific activity. The product with two subunits modified by PEG whose molecular weight is 40KDa has higher activity and longer half life. The conjugate is more suitable for preparation of antitumor drugs and application to clinic treatment.
Patients with hip arthritis, who are to be treated with total hip arthroplasty will be randomized in two groups. Patents allocated to study group will get their acetabular components implanted with the help of electromagnetic navigation system. Patients allocated to the control group will get their acetabular components implanted with freehand technique. Accuracy and precision of implanted acetabular components will be assessed on images obtained by postoperative computed tomography. Postoperative inclination and anteversion angles of acetabular components will be measured by the independent technician. Results will be statistically analyzed and compared.
Severe, early-onset fetal growth restriction (FGR, \<32 weeks gestation) is a condition in which the fetus does not reach its growth potential due to placental insufficiency\[. This condition affects about 0.3% of pregnancies, accounting for an estimated 15,000 babies in Europe being born premature below 32 weeks gestation. The main clinical dilemma of FGR lies in the timing of birth, given the balance of risks of antenatal mortality and severe damage to organs and the aggravated neonatal effects of prematurity: death or survival with severe neurodevelopmental impairment. The mainstay of clinical management in these cases pivots around the anticipation of the risk of fetal demise from placental oxygenation failure. The monitoring variables that are currently available comprise assessment of the severity of metabolic insufficiency (fetal size and growth, Doppler ultrasound, serum biomarkers) and the early detection of progressive fetal hypoxia with cardiotocography (CTG). The common approach is to deliver the fetus when signs of advanced hypoxia appear on CTG. A delicate balance exists between having the fetus born (too) early and facing the risks of extreme prematurity combined with a very low birthweight; and between delivering the fetus (too) late when the fetus has the disadvantage of hypoxia at birth. The decision when to deliver the fetus, is made mostly based on the CTG. The inter- and intra-observer variability could be overcome by software analysis according to the original Dawes\&Redman algorithm. The software calculates the short-term variation (STV) of the inter-beat interval expressed in milliseconds, and a range of secondary calculations. In contrast with repeated decelerations, when fetal hypoxia is considered evident, the place of the software analysis of the fetal heart rate variability is less clear. Although the advantages of mathematized and uniform quantification of the fetal heart rate variability appear self-evident, there are no studies with sufficient power to detect an association of intervention based on STV at any threshold with the most important outcomes: fetal death and long-term infant outcome.

The purpose of this study is to assess the outcomes of monitoring the fetal condition with STV in computerized CTG compared to visual interpretation of the CTG in order to time delivery in pregnant women with severe, early-onset FGR.
An executive committee will oversee the entire project. This committee, led by the nominated PI and Director of Nursing, will meet every 4 weeks during this four-year project. The team may include, depending on the hospital site: an administrator, the ED Director, the ED Head nurse, a community and/or hospital-based geriatric nurse specialist, an ED physician, a hospitalist, a geriatrician, a family physician, a home care nurse/coordinator, an inpatient unit manager, the research coordinator, and a local patient/caregiver. Each local team will be responsible for selecting and implementing the ACE intervention(s) best suiting their milieu, and will include locally identified champions to lead the local implementation.
After atraumatic extraction, flapless immediate implant of a suitable size will be placed using sequential drills of the Straumann implant system for osteotomy preparation. According to the prosthetically driven planned position, implant will be placed. Primary stability of the implant will be measured by rotational insertion torque, to be more than or equal 30 Ncm. All patients will receive an immediate anatomical customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
The recurrence of low-stage lung cancer poses a challenge due to its unpredictable nature and diverse patient responses to treatments. Personalized care and patient outcomes heavily rely on early relapse identification, yet current predictive models, despite their potential, lack comprehensive genetic data. This inadequacy fuels our research focus-integrating specific genetic information, such as pathway scores, into clinical data. Our aim is to refine machine learning models for more precise relapse prediction in early-stage non-small cell lung cancer. To address the scarcity of genetic data, we employ imputation techniques, leveraging publicly available datasets such as The Cancer Genome Atlas (TCGA), integrating pathway scores into our patient cohort from the Cancer Long Survivor Artificial Intelligence Follow-up (CLARIFY) project. Through the integration of imputed pathway scores from the TCGA dataset with clinical data, our approach achieves notable strides in predicting relapse among a held-out test set of 200 patients. By training machine learning models on enriched knowledge graph data, inclusive of triples derived from pathway score imputation, we achieve a promising precision of 82% and specificity of 91%. These outcomes highlight the potential of our models as supplementary tools within tumour, node, and metastasis (TNM) classification systems, offering improved prognostic capabilities for lung cancer patients. In summary, our research underscores the significance of refining machine learning models for relapse prediction in early-stage non-small cell lung cancer. Our approach, centered on imputing pathway scores and integrating them with clinical data, not only enhances predictive performance but also demonstrates the promising role of machine learning in anticipating relapse and ultimately elevating patient outcomes.
[Problem]  Provided is a compound which is useful as an active ingredient for a pharmaceutical having a PKC.theta. inhibition activity, particularly a pharmaceutical composition for inhibiting acute rejection occurring in transplantation.   [Means for Solution] The present inventors have conducted extensive studies on a compound having a PKC.theta. inhibition activity, and as a result, they have found that a compound having a structure such as aralkyl and the like on an amino group at the 2-position and also having a structure such as an adamantylalkyl group and the like on an amino group at the 4-position of 2,4-diaminopyrimidine, or a salt thereof has an excellent PKC.theta.  inhibition activity, thereby completing the present invention. The 2,4-diaminopyrimidine compound of the present invention can be used as a PKC.theta. inhibitor or an inhibitor of acute rejection occurring in transplantation.
The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered.
Embodiments may relate to an intelligent patient monitoring system, which may include a weight support device, a computer, and a display. The weight support device supports a patient and includes a sensor grid layer with a plurality of sensors to measure pressure data. The computer predicts a pressure injury outcome and/or a fall outcome based on the pressure data. The pressure injury outcome includes a prediction of risk of the patient developing a pressure injury. The fall outcome includes a prediction of risk of the patient experiencing a fall. The computer may utilize a machine learning model to determine either or both outcomes. The display presents a notification generated based on the pressure injury outcome or fall outcome. The notification indicates that an adjustment of a positioning of the patient is needed to aid in the prevention of the pressure injury or the fall.
The findings of the last decade suggest a complex link between inflammatory cells, coagulation, and the activation of platelets and their synergistic interaction to promote venous thrombosis. Inflammation is present throughout the process of venous thrombosis, and various metabolic pathways of erythrocytes, endothelial cells, and immune cells involved in venous thrombosis, including glucose metabolism, lipid metabolism, homocysteine metabolism, and oxidative stress, are associated with inflammation. While the metabolic microenvironment has been identified as a marker of malignancy, recent studies have revealed that for cancer thrombosis, alterations in the metabolic microenvironment appear to also be a potential risk. In this review, we discuss how the synergy between metabolism and thrombosis drives thrombotic disease. We also explore the great potential of anti-inflammatory strategies targeting venous thrombosis and the complex link between anti-inflammation and metabolism. Furthermore, we suggest how we can use our existing knowledge to reduce the risk of venous thrombosis.
Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy (SMT) .
The invention discloses a drug for treating qi stagnation and blood stasis-type thoracic obstruction. The drug comprises, by weight, 30-80 parts of radix bupleuri, 1-20 parts of radix scutellariae, 25-50 parts of red sage root, 1-20 parts of green tangerine peel, 20-30 parts of radix curcumae, 20-50 parts of lily, 1-50 parts of rhizoma corydalis, 1-30 parts of faeces trogopterori, 20-30 parts of white peony root, 1-20 parts of semen brassicae, 1-10 parts of peach seed and 10-16 parts of snakegourd seed. The drug is used for treating thoracic obstruction pain and has substantial effects by promoting blood circulation to remove blood stasis and dredging blood vessel. The preparation method of an oral liquid containing the drug has simple processes. The leached oral liquid can be fast absorbed by the human body and produce effects fast. Through a condensation technology, an oral liquid dosage is reduced and the oral liquid is convenient for carrying, preservation and taking.
Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
In the present invention, there are disclosed copper complexes in oxidation stage +II and crystal solvates thereof comprising a structural motif I of the general formula II or III expressed by the structural formulae [Cu(L1)(L2)] II or [Cu(L1)(L3)i2] III, wherein the symbol L1 represents a 2-phenyl-3-hydroxyquinolin-4(1H)-one of the general formula IV, L2 denotes a bidentately coordinating N-donor ligand and L3 represents a monodentately coordinating N-donor ligand to a copper atom of the base motif I, wherein the substituents R1 and R2 are independently selected from the group consisting of : a hydrogen atom, a halogen, an alkyl group, a substituted alkyl group, an amino group, a carboxamido group or another functional group or combination of these substituents, wherein the amino group can be further substituted as N-R?-R??, in which R? and R?? represent independently on each other a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, a substituted cycloalkyl group, a cycloheteroalkyl group, a substituted cycloheteroalkyl group, a heteroaryl group, and a substituted heteroaryl group, wherein the carboxamido group can also be further substituted as CO-N-R???, in which R??? denotes a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, a substituted cycloalkyl group, a cycloheteroalkyl group, a substituted cycloheteroalkyl group, a heteroaryl group, and a substituted heteroaryl group, and L2 and L3 represent ligands coordinating to a copper atom via a nitrogen atom or atoms.